Ladenburg Thalmann Financial Services’s Blueprint Medicines BPMC Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$66K	Sell	826 -101	-11%	-$7.56K	﹤0.01%	3328
2019 Q3	$68K	Sell	927 -170	-15%	-$14.7K	﹤0.01%	3209
2019 Q2	$104K	Buy	1,097 +423	+63%	+$34.9K	﹤0.01%	2945
2019 Q1	$54K	Buy	674 +565	+518%	+$41.8K	﹤0.01%	3353
2018 Q4	$6K	Buy	109 +42	+63%	+$2.55K	﹤0.01%	4497
2018 Q3	$5K	Buy	67 +17	+34%	+$1.18K	﹤0.01%	4579
2018 Q2	$5K	Hold	50	–	–	﹤0.01%	4569
2018 Q1	$5K	Sell	50 -145	-74%	-$12.5K	﹤0.01%	4569
2017 Q4	$15K	Buy	195 +50	+34%	+$3.52K	﹤0.01%	3954
2017 Q3	$10K	Buy	+145	New	+$7.75K	﹤0.01%	4070

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ladenburg Thalmann Financial Services's BPMC Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services reduced its Blueprint Medicines (BPMC) stake by 11% in Q4 2019, selling an estimated $7.56K and leaving 826 shares worth $66K. The position accounts for ﹤0.01% of the portfolio, ranked #3328.

Ladenburg Thalmann Financial Services first reported a position in BPMC in Q3 2017 and has held it in 10 quarters since. The position peaked at $104K in Q2 2019. 228 funds tracked by Wall St. Rank hold BPMC as of Q4 2019.

Ladenburg Thalmann Financial Services held 826 shares of Blueprint Medicines worth $66K as of Q4 2019.
Ladenburg Thalmann Financial Services sold 101 Blueprint Medicines shares in Q4 2019, an estimated $7.56K.
Blueprint Medicines made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #3328 holding.
Ladenburg Thalmann Financial Services first reported a position in Blueprint Medicines in Q3 2017 and has held it in 10 quarters since.
Ladenburg Thalmann Financial Services's Blueprint Medicines position peaked at $104K in Q2 2019.
228 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.